Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures
2004-000483-27Phase 3Completed
- Sponsor
- BIAL
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eslicarbazepine acetate in Focal Onset Epilepsy (4 arms), sponsored by BIAL. Primary endpoint: Seizure frequency during maintenance (primary). Started Jun 2004; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2004-000483-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000483-27.